Capricor Therapeutics (CAPR) Stock: Holds Steady As Lancet Publication Validates Deramiocel’s Phase 3 Success

TLDR Capricor Therapeutics stock stays flat at $6.57 after Lancet publishes HOPE-3 data. The Lancet’s peer review confirms Deramiocel’s Phase 3 trial design and results. UC Davis expert calls HOPE-3 results a landmark for Duchenne patients everywhere. Capricor CEO says Lancet publication strengthens the company’s FDA approval case. FDA’s Deramiocel decision looms August 22 as [...]

The post Capricor Therapeutics (CAPR) Stock: Holds Steady As Lancet Publication Validates Deramiocel’s Phase 3 Success appeared first on Blockonomi.